TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility Study (Xenograft)
Primary objectives:
- Evaluate the feasibility of rapidly accruing 30 participants with recurrent metastatic head and neck squamous cell carcinoma for the development of patient derived xenographs (PDX) from fresh, real time biopsies in which sensitivity to < 4 Ontario funded chemotherapeutic regimen will be tested. Written feedback to the primary oncologist will be provided.
- There is also a curative intent cohort of 30 participants undergoing surgical resection with curative intent. These PDX models will undergo exome sequencing with written feedback.
- Feasibility in both surgical and recurrent cohorts will be a measure of i) engraftment rate, ii) patient status at the time of drug testing completion and iii) rate of accrual.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 4L6
- London Regional Cancer Program
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with recurrent metastatic squamous cell carcinoma of the head and neck.
- Lesion amenable to biopsy (1 cm or more)
- Lesion capable of yielding 4 biopsy cores
- 18 years or older
- Capable of providing and signing for informed consent
Exclusion Criteria:
- Cognitive impairment prohibitive to providing informed consent
- Pregnant or lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: HNSCC -PDX development
Participants with HNSCC who will undergo curative surgery will be included in this group.
This involves PDX development only, no drug testing will be done on the PDX.
|
Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)
|
|
Other: RMHNSCC -PDX drug testing
Participants with RMHNSCC who are under palliative treatment will be included in this group.
Drug testing on PDX per Investigator's choice (upto 4): PDX will be developed and upto four Chemotherapeutics (that are funded in Ontario) will be tested on the PDX.
Chemotherapeutics will be selected at the discretion of the treating Medical Oncologists.
Result of the drug testing will be provided to the responsible physician and can be utilized in patient care.
|
Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To determine the rate of PDX engraftment for HNSCC and RMHNSCC samples
Time Frame: 1-2 years
|
1-2 years
|
|
|
Time to engraftment
Time Frame: 1-2 years
|
1-2 years
|
|
|
Percentage of models successfully undergoing drug testing
Time Frame: 1-2 years
|
1-2 years
|
|
|
Participant status at the time of completion of drug testing
Time Frame: 1-2 years
|
Participant status at the time of completion of drug testings(i.e.
what percentage of participants are alive and well enough to receive further chemo).
|
1-2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Anthony Nichols, MD, FRCSC, London Regional Cancer Program
- Principal Investigator: Eric Winquist, MD, FRCPC, London Regional Cancer Program
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 106515
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.